Sangamo Therapeutics

500 articles with Sangamo Therapeutics

• 

  More Hacks Inevitable in Pharma Industry, Cybersecurity Expert Says

  5/22/2019

  Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.

• Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences

  5/15/2019

  Hemophilia A SB-525 gene therapy clinical data accepted for oral presentation at ISTH

• Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference

  5/10/2019

  Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sangamo will participate in the Bank of America Merrill Lynch 2019 Health Care Conference being held next week in Las Vegas

• Sangamo Therapeutics Reports First Quarter 2019 Financial Results

  5/8/2019

  Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights.

• Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast

  5/1/2019

  Sangamo Therapeutics, Inc. announced that the Company will release its first quarter 2019 financial results after the market closes on Wednesday, May 8, 2019.

• Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - April 8, 2019

  4/8/2019

  Sangamo Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.

• Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock

  4/4/2019

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share.

• Sangamo Therapeutics Announces Proposed Public Offering of Common Stock

  4/3/2019

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock.

• 

  Sangamo Jumps 28 Percent on Positive Early Hemophilia Trial Data

  4/3/2019

  The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.

• Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data

  4/2/2019

  Conference call and webcast scheduled for 8:00 a.m. Eastern Time

• Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio

  4/2/2019

  Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies

• Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

  4/2/2019

  Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels

• Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update

  4/1/2019

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will host a conference call on Tuesday, April 2nd at 8:00 a.m. Eastern Time to provide a clinical development update.

• Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology

  3/29/2019

  Data presented at ADPD show that tau-targeted ZFP-TFs delivered with AAVs in mice and nonhuman primates have significant activity

• 

  10 Immuno-Oncology Deals Worth Talking About

  3/26/2019

  Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
• 

  BioSpace Movers and Shakers: March 22

  3/22/2019

  Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.

• Sangamo Therapeutics Appoints Jason Fontenot, Ph.D., As Senior Vice President, Cell Therapy

  3/12/2019

  Sangamo Therapeutics, Inc., a genomic medicine company, announced the appointment of Jason Fontenot, Ph.D., as Senior Vice President, Cell Therapy.

• Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing

  3/8/2019

  Data published in Nature Communications show new architectures increase targeting capabilities by 64-fold

• Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences

  3/6/2019

  Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will participate in the following healthcare investor conferences in March

• Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

  2/28/2019

  Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time